Health Canada has authorized the use of Celltrion's Steqeyma®, a biosimilar of Stelara® (ustekinumab), for managing various persistent inflammatory diseases.

Vaccinex Announces Promising Results from SIGNAL-AD Phase 1b/2 Trial of Pepinemab for Alzheimer's Disease.

Myeloid Therapeutics begins administering MT-303, a new RNA CAR targeting GPC3, in a Phase 1 trial for late-stage hepatocellular carcinoma (HCC).

SanBio Gains Approval for "AKUUGO® Suspension for Intracranial Use" (INN: Vandefitemcel) to Treat Persistent Motor Paralysis from Traumatic Brain Injuries.

The combination therapy was well tolerated, and the safety profile of BNT111 with cemiplimab was consistent with previous trials of BNT111 with anti-PD-(L)1-based treatments.

Tectonic Therapeutic has announced that the U.S. Food and Drug Administration has approved its Investigational New Drug application for TX45.

FibroGen Releases Main Outcomes from Two Advanced Pamrevlumab Pancreatic Cancer Trials and Shares Corporate News.

Umoja Biopharma Receives FDA Approval for IND Application of UB-VV111, a CD19 Targeted CAR T for Blood Cancers.

The European Medicines Agency (EMA) has given its approval to Bio-Thera Solutions for BAT1706 (Avzivi®, bevacizumab), a biosimilar of Avastin®.

Connext has revealed the initial successful administration of CNT201, its therapeutic solution for Dupuytren’s contracture, in patients.

Vertex reveals FDA approval of New Drug Application for Suzetrigine for treating moderate-to-severe acute pain.

PepGen reports encouraging results from low-dose group in ongoing CONNECT1-EDO51 Phase 2 trial for treating Duchenne Muscular Dystrophy with PGN-EDO51.